Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal
Reza Maleki-Yazdi, M., Molimard, Mathieu, Keininger, Dorothy L., Gruenberger, Jean-Bernard, Carrasco, Joao, Pitotti, Claudia, Sauvage, Elsa, Chehab, Sara, Price, DavidVolume:
14
Language:
english
Journal:
Applied Health Economics and Health Policy
DOI:
10.1007/s40258-016-0256-z
Date:
October, 2016
File:
PDF, 1.19 MB
english, 2016